Right now the infusions business and cardiocel povide the bread and butter revenue to make a going concern and hopefully will be a growth engine. Yes, if the vaccines proved successful it would make sense to buy back a controlling stake even at a higher price.
Thats just being pragmatic, and its the management decision making that has got Admedus back on its feet.
Letter of intent to fund Vacs, page-20
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.00 |
Change
0.000(0.00%) |
Mkt cap ! $253.6M | |||
| Open | High | Low | Value | Volume |
| $11.88 | $12.00 | $11.50 | $261.8K | 22.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 156 | $11.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.00 | 6045 | 3 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |